Sales Growth Continues At Merck AG
Merck AG of Switzerland achieved sales in the third quarter of 1994 of 2.13 billion Swiss francs ($1.7 billion), up 8% on the like, year-earlier period. In terms of local currencies, the company said that the sales increase amounted to 15%.
From May 1994, the new acquisition Merck Generics, which previously traded as Amerpharm, contributed around 65 million francs to the sales increase. Contributions to the expansion of business by the Bracco Group in the USA have not been included in these figures.
Sales by the pharmaceutical division improved 10% in Swiss franc terms and 18% in local currencies. The group's chemical division posted a sales increase of 14% (or 21% in local currencies), and laboratory products sales were ahead 1% (9% in local currencies). On a regional basis, Merck said that growth was strongest in Asia, up 19% (24% in local currency terms).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze